Navigation Links
Co-Promotion of a New Medical Device for Female Infertility Announced
Date:1/18/2011

SPARTANBURG, S.C., Jan. 18, 2011 /PRNewswire/ -- Norgenix Pharmaceuticals, LLC (www.norgenixpharma.com), a wholly owned subsidiary of Spartanburg-based J M Smith Corporation, and Fertility Focus Limited (www.fertility-focus.com) today announced a partnership for the co-promotion of the Fertiloscope, a CE marked and 510(k) approved surgical instrument for the early diagnosis and immediate corrective surgery of physical causes of female infertility. Norgenix has exclusive rights to market and distribute the Fertiloscope in the United States, as well as US territories and military bases. The product will benefit from the strategic support of Glenveigh Medical (www.glenveigh.com) as well, with whom Norgenix has an existing alliance in the U.S. to promote medical devices developed by Glenveigh.

Norgenix and Fertility Focus also announced a strategic alliance and revealed its first medical device co-promotion, the Fertiloscope. Norgenix is a North American specialty pharmaceutical, medical device and biotechnology company that engages in the development, commercialization, and sales of products in the women's health arena. Norgenix is licensed to sell, market, and distribute prescription drug products and medical devices in all 50 U.S. states. Fertility Focus is a United Kingdom based company that develops devices aimed at the infertility market.

Developed by the eminent French surgeon Dr. Antoine Watrelot, the Fertiloscope, is a novel laparoscope for minimally invasive trans-vaginal use in a procedure that is known as Fertiloscopy. The Fertiloscopeis the only method of primary screening that provides gold standard accuracy in a day-case or office setting. This relatively new surgical technique is used for the early diagnosis and immediate treatment of a number of disorders of the female reproductive organs.

Norgenix is dedicated to in-licensing product opportunities and building strategic alliances with companies interested in maximizing the value of products that fulfill unmet medical needs in the U.S. marketplace. As a strategic partner, Norgenix and the related J M Smith partner companies will provide strategic direction and capitalization to build success.MEDIA CONTACT:  Sims Hammond 864.580.2350 Sims@LaunchSomething.com
'/>"/>

SOURCE Norgenix Pharmaceuticals, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reportlinker Adds Co-promotion and Co-marketing Agreements in Pharma, Biotech and Diagnostics, 4th Edition
2. Nautilus Neurosciences and Mission Pharmacal Announce Exclusive Co-Promotion Agreement for CAMBIA™ (diclofenac potassium for oral solution) for the Acute Treatment of Migraine to the Womens Health Market
3. Warner Chilcott Agrees to Terminate Existing Co-Promotion Agreement and Acquire U.S. Rights to Enablex® Overactive Bladder Treatment for $400 Million in Cash
4. Lilly, Kowa and Kowa Pharmaceuticals America Announce Co-Promotion and Licensing Agreement
5. Timm Medical Technologies and Ferring Pharmaceuticals Enter Exclusive Co-Promotion Agreement for Prosed(R) DS
6. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
7. Octapharma Targets Primary Immune Deficiency Research With Grant for The Mount Sinai Medical Center
8. Rochester Medical Announces First Quarter 2011 Earnings Conference Call Tuesday, January 25, 2011
9. Vasomedical Reports Financial Results for the Quarter Ended November 30, 2010
10. Mindray Medical to Exhibit at Arab Health 2011 in Dubai from January 24-27
11. Emerging Markets Are Gaining Ground in Medical Technology Innovation; U.S. Maintains Lead, Finds PwCs Medical Technology Innovation Scorecard
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... 2016 Treato , the ... announced today that it has been named a Cool ... in Life Sciences, 2016, Stephen Davies , ... focuses on life-science- oriented analytics, algorithms and smart machine ... doctors, confirm medication ingestion, and analyze unstructured information.   ...
(Date:4/28/2016)... 28, 2016 Oramed Pharmaceuticals Inc. (NASDAQ: ... company focused on the development of oral drug delivery systems, ... PIONEERS 2016 conference, presented by Joseph Gunnar & ... New York . Nadav Kidron , CEO ... Presentation Details:   PIONEERS 2016, ...
(Date:4/28/2016)... TapImmune,Inc. (TPIV), a clinical-stage immune-oncology company ... and vaccines for the treatment of cancer & metastatic disease, ... Growth Capital Expo to be held on May 3 ... in Las Vegas, Nevada.  The Company presentation will be ... by Dr. John N. Bonfiglio a TapImmune Board ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... April 29, 2016 , ... In its efforts of bringing quality senior care ... franchise development and expansion as it welcomes Ferdie Vasquez of the new 1Heart Caregiver ... his 32 years of working in various industries. He had been a Franchise ...
(Date:4/28/2016)... ... 2016 , ... Sublime Beauty® is offering a special deal on its webstore. , Buy 1 ... is applied to the product with lesser value. In addition, a free bonus of ... more in products. , "So many women (men, too) love our products and get good ...
(Date:4/28/2016)... (PRWEB) , ... April 28, 2016 , ... ProText Layouts ... Final Cut Pro X . With ProText Layouts, video editors can create ... to match the length and scale of texts. Creating text-based videos have never ...
(Date:4/28/2016)... ... , ... Head Over Heels Athletic Arts’ gymnast, Brooklyn Varize, has qualified to ... at the University of Montana on April 28-May 1. Varize will compete on Saturday ... order to qualify, Varize needed to place top seven all-around in her respective age ...
(Date:4/28/2016)... ... 2016 , ... The ARRS 2016 Annual Meeting ... from around the globe who attended a week’s worth of cutting-edge scientific presentations, ... included the introduction of the 2016 ARRS Distinguished Educator, Dr. Gerald F. Abbott, ...
Breaking Medicine News(10 mins):